Here are 8 potential reasons why not to prescribe Lixisenatide: 1- this is only one small study and only one dose was tested, 2- Lixisenatide is not currently available at pharmacies, 3- the weight loss associated with this GLP-1 is not desirable in many cases of Parkinsons disease where weight loss is an issue, 4- non-motor outcomes did not change as in other trials, and this will need to be better explained
While the pharmaceutical world celebrates this "silence" as a breakthrough, we must have a more sophisticated conversation
Randomized clinical trial evaluating kinetic benefits of desensitizing agents: Magnitude, onset, and stability of relief
With Doctronic, you get the most up-to-date medical expertise without the wait
It is a continuous process that refrigeration slows but does not stop
ADPN is an adipokine that affects hepatic fat and glucose metabolism, which interacts with adiponectin receptor1 and adiponectin receptor 2